Düzen Selects Bruker Corporation´s MALDI Biotyper for Mass Spectrometry-based Molecular Microbial Identification

ANKARA, Turkey--(BUSINESS WIRE)--At the 7th National Molecular and Diagnostic Microbiology Congress in Ankara, Bruker announces an exclusive framework agreement with Düzen (www.duzen.com.tr) in the area of molecular microbial identification based on MALDI-TOF mass spectrometry. Düzen is one of the leading private diagnostic laboratory groups in Turkey, and Bruker is the leading provider of mass spectrometry-based microorganism identification solutions worldwide. Düzen Laboratories, a highly regarded clinical diagnostics company for 38 years, is the pioneer in its field in introducing new technologies into routine clinical use in Turkey. In addition, Düzen also supports government and university funded health programs, and is the contract service provider of several embassies for visa applications.